BeiGene Acquires Property in New Jersey to Build Manufacturing and Clinical R&D Center

Published on: 

BeiGene has acquired property in Hopewell, NJ to build a new manufacturing site and clinical R&D center for advanced new medicines.

BeiGene, a biotechnology company, has purchased a 42-acre site at the Princeton West Innovation Campus in Hopewell, NJ, on which it will build a new state-of-the-art manufacturing campus and clinical R&D center for advanced medicines. The company states in a Nov. 23, 2021 press release that it is investing in US manufacturing to expand and diversify its global supply chain and build new manufacturing capabilities for its biologics and drug pipeline.

BeiGene expects to invest several hundred million dollars in the initial phase of construction at the Hopewell site as well as the acquisition of the property, pending finalization of development plans. The new facility is expected to include up to approximately 400,000 ft2 of dedicated commercial-stage biologic pharmaceutical manufacturing. It will house up to 16,000 L of biologics capacity, along with clinical R&D and office space.

The initial phase of construction is expected to begin in 2022, with completion slated in late-2023 or in 2024. The property will additionally have more than one million square feet of developable real estate for potential future expansion.

“With this property acquisition, we plan to establish a flagship manufacturing and clinical R&D center in the [United States] to diversify our global supply chain. We are proud to take this next step in our journey to advance impactful treatments and make them more accessible to patients around the world,” said John V. Oyler, co-founder, chairman, and CEO of BeiGene, in the company press release. “We have already begun hiring additional colleagues from the deep talent pool in New Jersey and look forward to serving as a member of the thriving Princeton-Hopewell business community.”


“We are extremely excited that BeiGene has taken the next step in the company’s push to manufacture innovative cancer medicines right here in New Jersey,” said Governor Phil Murphy, in the press release. “Our goal since day one has been to create an environment in New Jersey that fosters the growth of companies [such as] BeiGene, and we are excited to see what’s next as the company expands.”

“BeiGene's expertise in developing innovative cancer treatments combined with their planned state-of-the-art facility makes this a win-win-win for Hopewell, BeiGene, and the millions of cancer patients whose lives will hopefully improve from BeiGene medicines. We are proud that those medicines will be manufactured right here," said Hopewell Township Mayor Julie Blake, in the press release.

Source: BeiGene